STAT+: Pharmalittle: We’re reading about a pharma job slowdown, diet drugs boosting GDP, and more
The widespread use of new weight loss drugs in the U.S. could boost gross domestic product by 1% through a boost in workplace efficiency.
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda appears quite modest so far. We plan to promenade with the official mascots, catch up on our napping and maybe finish an overdue library book. There might also be a listening party, and the rotation will likely include this, this, this, this and this. And what about you? This may be a fine time to tackle your own reading list or binge-watch by the telly. You could plan a spring break or, if you feel ambitious, maybe the rest of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …
The widespread use of new weight loss drugs in the U.S. could boost gross domestic product by 1% in the coming years as lower obesity-related complications are likely to boost workplace efficiency, Reuters writes, citing a Goldman Sachs forecast. Some analysts have predicted the market for weight loss drugs could reach $100 billion a year by the end of the decade, with Ozempic maker Novo Nordisk and Mounjaro producer Eli Lilly leading the race. The brokerage estimated weight loss drugs could bolster U.S. gross domestic product by 0.4% in a scenario with 30 million users, and could rise to 1% with 60 million users.
Worldwide hiring in the biopharma industry has been slowing since mid-2022, according to RBC Capital Markets analysts. This may reflect a greater focus on costs given inflation, IRA concerns, smaller companies trimming pipelines, biopharma layoffs, and near-term patent cliffs for the industry as a whole. But jobs are being filled faster and a bigger focus on jobs outside the U.S. may reflect a push to drive more diversified revenues and expand the pharmaceutical market, though may expose companies to additional political, regulatory, and foreign exchange risk. Meanwhile, there are no major changes seen to job mix across R&D, manufacturing, commercial or administrative roles.
What's Your Reaction?
